Home > Dermatology > AAD 2018 > Alopecia Areata > New agents and combination therapy

New agents and combination therapy

Presented By
Prof. Wilma Bergfeld, Cleveland Clinic
Conference
AAD 2018

Many new agents in the pipeline

Another interesting agent is a novel peptide that inhibits the cytokines IL-2, IL-9, and IL-15 (BNZ-1). Signalling of IL-4, IL-7, and IL-21 are unaffected by this peptide, which preserves immunological function (Figure 11). The agent BNZ-1 was effective in a mouse model of immune-mediated hair loss. It led to a reduction of the inflammatory cytokines IL-6, TNF-α and IFNγ and was able to restore hair growth. It proved to be safe in healthy volunteers and a Phase 2 randomised double-blind placebo-controlled dose ranging study in AA is planned in 2018.

“Many pharma companies are now interested in hair disorders and in the hair follicle as a model to study inflammatory pathways, so there is more to come in the next years,” said Prof. Wilma Bergfeld of the Cleveland Clinic

Figure 11: Mode of action of the peptide BNZ-1



Posted on